Front-line combination with quizartinib has also been evaluated in the double-blind phase 3 QuANTUM-First trial [122], and its press release announced superior overall survival compared with standard therapy (DNR/AraC or IDA/AraC) alone in patients with newly diagnosed FLT3-mutated AML [123]. The gene discussed is FLT3; the disease is acute myeloid leukemia.